Monitoring lung cancer after treatment to predict return
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether checking for tiny traces of cancer left in the blood (called minimal residual disease) after treatment can tell if lung cancer might come back. It may help doctors decide how often to monitor patients in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (a common type of lung cancer).
- Your cancer is early to mid-stage (stage IB to III) and can be treated with surgery, or you are having chemotherapy and radiation with the goal of curing it.
- You are at least 18 years old.
- You are able to provide tissue and blood samples.
- You have not had another active cancer in the last 3 years, with some exceptions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
This study tests whether a simple blood test (liquid biopsy) can help doctors monitor for cancer returning after surgery for early-stage lung cancer. It is for people with non-small cell lung cancer that can be removed with surgery.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
Hear when a new NSCLC, Stage I, II, III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.